FoRx Therapeutics Secures $50M Series A to Advance Precision Cancer Drug

Why It Matters

The infusion of $50 million fast‑tracks a novel DDR‑targeted therapy toward clinical proof, potentially expanding treatment options for resistant cancers and delivering significant upside for investors in precision oncology.

Key Takeaways

• FoRx secured $50M Series A funding.
• Investors include EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund.
• Funds will advance Phase 1 of FORX-428.
• FORX-428 targets PARG, disrupting DNA damage response.
• Preclinical data shows robust activity across solid tumors.

Pulse Analysis

FoRx Therapeutics’ $50 million Series A round underscores the growing appetite for precision‑oncology platforms that address unmet needs in treatment‑resistant cancers. Backed by heavyweight investors such as EQT Life Sciences, Pfizer Ventures and Novartis Venture Fund, the Swiss‑based biotech is positioned to leverage deep expertise in DNA‑damage response (DDR) biology. The capital infusion not only validates the scientific premise of PARG inhibition but also reflects broader market confidence in novel, oral small‑molecule therapeutics that can be paired with existing regimens.

PARG, the enzyme that reverses poly‑ADP‑ribose chains, has emerged as a compelling target after extensive research highlighted its role in sustaining cancer cells with high replication stress or DDR deficiencies. FORX‑428, FoRx’s lead candidate, differentiates itself by offering oral bioavailability and a safety profile that could enable combination strategies with PARP inhibitors or immunotherapies. Early preclinical models demonstrate tumor regression across multiple solid‑tumor histologies, suggesting a potential best‑in‑class positioning that could reshape treatment algorithms for advanced disease.

The financing milestone accelerates the transition from IND filing to Phase 1 enrollment, a critical juncture for clinical validation and de‑risking. Successful early‑stage results would likely attract follow‑on capital and strategic partnerships, intensifying competition among biotech firms targeting the DDR axis. For investors, FoRx represents a high‑growth opportunity at the intersection of innovative biology and scalable drug development, with the prospect of delivering a differentiated oral therapy to a market hungry for new options.

Deal Summary

Swiss biotech FoRx Therapeutics announced the closing of a $50 million Series A round, backed by EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures. The funding will support Phase 1 development of its PARG inhibitor FORX‑428 for advanced solid tumors.